Early dexamethasone treatment after implantation of a sciatic-nerve cuff decreases the concentration of substance P in the lumbar spinal cord of rats with neuropathic pain.
The main purpose of this study was to evaluate the effects of early dexamethasone treatment on pain-related peptides at an early stage in the development of neuropathic pain induced by implantation of a sciatic nerve cuff in Sprague Dawley rats (body weight 250 to 350 g). The rats were tested for touch sensitivity with the use of von Frey filaments before and 3 d after cuff implantation (n = 12) or sham surgery (n = 6). Half of the cuff-implanted rats received dexamethasone, 1 mg/kg intraperitoneally, 1 h after surgery. Spinal cords were collected on the 3rd day after surgery, and the lumbar enlargement was processed for the detection of selected peptides (neurotensin, substance P, cholecystokinin [CCK], vasoactive intestinal peptide, and calcitonin gene-related peptide) by means of liquid chromatography and tandem mass spectrometry. The right sciatic nerve of each rat was collected, fixed, and stained for histopathological evaluation. Except for neurotensin, all the peptides showed an increased concentration with neuropathic pain; however, the differences were significant (P < 0.05) only for substance P and CCK. In the animals treated with dexamethasone, mechanical allodynia was less pronounced (P < 0.01), and only the concentration of substance P was decreased significantly (P < 0.05). Sciatic nerve sections showed a decrease in C (P < 0.01) and Adelta (P < 0.03) fibres with neuropathic pain and a nearly normal percentage of C fibres after dexamethasone treatment. The dexamethasone-treated animals also had less inflammation detectable microscopically at the nerve constriction site compared with cuff-implanted animals that were not treated with dexamethasone. Our results suggest that in the early stages of neuropathic pain induced by an inflammatory process, dexamethasone may be a useful treatment and that substance P plays an important role in pain perception.
Beaudry
Francis
F
Université de Montréal, Faculté de Médecine Vétérinaire, Départements de Biomédecine Vétérinaire et de Pathologie et Microbiologie, Saint-Hyacinthe, Québec.
Girard
Christiane
C
Vachon
Pascal
P
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D002116:Calcitonin / Q000032:analysis / Q000378:metabolism; D002766:Cholecystokinin / Q000032:analysis / Q000378:metabolism*; D002853:Chromatography, Liquid; D003250:Constriction; D003907:Dexamethasone / Q000627:therapeutic use*; D004195:Disease Models, Animal; D008297:Male; D013058:Mass Spectrometry; D009412:Nerve Fibers / Q000378:metabolism; D009496:Neurotensin / Q000032:analysis / Q000378:metabolism; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D012584:Sciatic Nerve / Q000293:injuries; D020426:Sciatic Neuropathy / Q000188:drug therapy / Q000662:veterinary*; D013116:Spinal Cord / Q000378:metabolism* / Q000473:pathology; D013373:Substance P / Q000032:analysis / Q000378:metabolism*; D013997:Time Factors; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D013373:Substance P; D009496:Neurotensin; D003907:Dexamethasone; D002116:Calcitonin; D002766:Cholecystokinin